
WHAT IS CLAIMED IS:


1. Use of a compound of formula (I):



(I),

or a pharmaceutically effective salt, ester or prodrug thereof in the manufacture of a medicament for the treatment of a disease associated with insulin resistance selected from a nonalcoholic fatty liver disease (NAFLD), a lipodystrophic syndrome or a combination thereof in a subject.

2. The use of claim 1, wherein vitamin E is to be further administered to the subject.
3. The use of claim 2 wherein the medicament and vitamin E are to be administered concomitantly, simultaneously or consecutively.
4. The use of claim 2 wherein the amount of the compound of formula I is from about 0.1 to about 10.0 milligrams ("mg") per day and wherein the amount of vitamin E is from about 1 to about 10,000 international units ("IU") per day.
5. The use of claim 4 wherein the amount of the compound of formula I is from about 1 mg to about 2 mg and the amount of vitamin E is from about 400 to about 1,000 IU per day.
6. The use of claim 5 wherein the amount of the compound of formula I is about 1 or about 2 mg per day and the amount of vitamin E is about 400, about 800 or about 1,000 IU per day.
7. Use of a compound of formula (I):




(I),

or a pharmaceutically effective salt, ester or prodrug thereof in the manufacture of a medicament for the treatment of a nonalcoholic fatty liver disease (NAFLD) in a subject.


8. The use of claim 7 wherein the subject is a human.
9. The use of claim 7 wherein the NAFLD is simple nonalcoholic fatty liver (NAFL).


10. The use of claim 9 wherein the NAFLD is NAFL with attendant liver fibrosis.
11. The use of claim 9 wherein the NAFLD is NAFL with attendant liver cirrhosis.
12. The use of claim 7 wherein the NAFLD is nonalcoholic steatohepatitis (NASH).
13. The use of claim 12 wherein the NAFLD is NASH with attendant liver fibrosis.
14. The use of claim 12 wherein the NAFLD is NASH with attendant liver cirrhosis.
15. The use of claim 7 wherein the amount of formula (I) is from about 0.1 to about 10.0 mg per day.
16. The use of claim 15 wherein the amount of formula (I) is about 1 mg per day.
17. The use of claim 15 wherein the amount of formula (I) is about 2 mg per day.
18. The use of claim 1 wherein the use provides an NAFLD activity score (NAS) of 7 or less.
19. The use of claim 18 wherein the NAS is 5 or less.
20. The use of claim 18 wherein the NAS is 3 or less.
21. A pharmaceutical composition for the treatment of a disease associated with insulin resistance selected from a nonalcoholic fatty liver disease (NAFLD), a lipodystrophic syndrome or a combination thereof comprising the compound of claim 1 and a pharmaceutically acceptable excipient.
22. The pharmaceutical composition of claim 21 wherein the disease associated with insulin resistance is an NAFLD.
23. The pharmaceutical composition of claim 21 wherein the disease associated with insulin resistance is a lipodystrophic syndrome.
24. Use of a compound of formula (I):



(I),

or a pharmaceutically effective salt, ester or prodrug thereof in the manufacture of a medicament for the treatment of a lipodystrophic syndrome in a subject.
25. The use of claim 24 wherein the lipodystrophic syndrome is a generalized lipodystrophy.
26. The use of claim 25 wherein the generalized lipodystrophy is a congenital generalized lipodystrophy.
27. The use of claim 25 wherein the generalized lipodystrophy is an acquired generalized lipodystrophy.

28. The use of claim 24 wherein the lipodystrophic syndrome is a congenital partial lipodystrophy.
29. The use of claim 24 wherein the lipodystrophic syndrome is an acquired partial lipodystrophy.
30. Use of a compound of formula (I): 

(I),
or a pharmaceutically effective salt, ester or prodrug thereof in the manufacture of a medicament for the treatment of hyperlipidemia in a subject suffering from a lipodystrophic syndrome and hyperlipidemia .
31. The use of claim 30 wherein the subject is further suffering from a nonalcoholic fatty liver disease (NAFLD).
32. Use of a compound of formula (I): 

(I),
or a pharmaceutically effective salt, ester or prodrug thereof in the manufacture of a medicament for the treatment of hyperglycemia in a subject suffering from a lipodystrophic syndrome and hyperglycemia.
33. The use of claim 32 wherein the subject is further suffering from a nonalcoholic fatty liver disease (NAFLD).